In addition to Mafs regulator related drugs, β-glucans, a newly discovered natural compound targeting c-Maf, delays tumor growth by transforming M2-like macrophages into an M1-like phenotype that corresponds with downregulated c-Maf levels in non–small cell lung cancer. The gene discussed is MAF; the disease is lung cancer.